Table 5.

Multivariate analysis of ≥15 letters gain from baseline at 6 months.

Predictors	N	n (%)	OR (95% CI)	P
Baseline VA score
<20 letters	23	10 (43.5)	1.000	0.028
20–39 letters	56	25 (44.6)	0.688 (0.227–2.091)
40–59 letters	45	9 (20.0)	0.277 (0.081–0.944)
≥60 letters	20	2 (10.0)	0.107 (0.018–0.638)
Duration of neovascular AMD
<1 month	5	4 (80.0)	1.000	0.092
1–6.9 months	70	22 (31.4)	0.105 (0.010–1.113)
7–12 months	26	10 (38.5)	0.134 (0.012–1.542)
>12 months	31	5 (16.1)	0.047 (0.004–0.571)
ARMS2 rs10490924
GG	16	6 (37.5)	0.742 (0.190–2.897)	0.021
GT	44	21 (47.7)	1.000
TT	83	19 (22.9)	0.284 (0.114–0.706)

AMD: age-related macular degeneration; CI: confidence interval; OR: odds ratio; VA: visual acuity.

Variables included in step 1 are age group, gender, baseline VA score, duration of neovascular AMD, ARMS2 rs10490924 genotype, and treatment regimen.